Can venetoclax/venetoclax cure leukemia?

Venetoclax/Venetoclax (Venetoclax) is an oral targeted drug targeting the B-cell lymphoma 2 (BCL-2) protein. It is mainly used to treat certain types of acute and chronic leukemias, especially chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Its mechanism of action is to promote the apoptosis of cancer cells by selectively inhibiting BCL-2 protein. For many patients, the introduction of venetoclax marks a new phase in leukemia treatment.

In clinical trials, venetoclax has shown promising efficacy, particularly in treating patients who are intolerant to conventional chemotherapy or who have received multiple treatments. For chronic lymphocytic leukemia, venetoclax is often used in combination with other drugs, such as the monoclonal antibody alemtuzumab (Obinutuzumab), which significantly improves the remission rate and survival time of patients. In addition, venetoclax is being studied as an effective treatment option for acute myeloid leukemia, especially when used in combination with chemotherapy drugs.

However, although venetoclax has shown promising results in many patients, whether it can "cure" leukemia depends on a variety of factors, including the type of leukemia, the patient's overall health, the stage of the disease, and the individual's response to treatment. In some cases, venetoclax may lead to complete remission or even long-term disease-free survival, but this does not represent a complete cure. Certain types of leukemia, such as chronic lymphocytic leukemia, are often chronic and relapsing in nature, so regular monitoring is needed even after treatment with venetoclax to prevent recurrence of the disease.

In addition, the use of venetoclax is also associated with certain risks of side effects, including tumor lysis syndrome, increased risk of infection, and thrombocytopenia. Therefore, when treating with venetoclax, doctors carefully evaluate the patient's condition and health to develop an individualized treatment plan.

Reference materials:https://www.cancernetwork.com/view/navigating-a-paradigm-shift-venetoclax-treatment-redefines-landscape-of-acute-myeloid-leukemia